Nektar Therapeutics/$NKTR
13:30
21:10
04:45
12:25
20:00
1D1W1MYTD1Y5YMAX
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.
Ticker
$NKTR
Sector
Primary listing
Employees
63
Headquarters
Website
NKTR Metrics
BasicAdvanced
$2.7bn
-
-$8.09
1.25
-
Price and volume
Market cap
$2.7bn
Beta
1.25
52-week high
$109.00
52-week low
$7.99
Average daily volume
1.1m
Financial strength
Current ratio
10.207
Quick ratio
9.853
Long term debt to equity
20.982
Total debt to equity
24.892
Interest coverage (TTM)
-4.28%
Profitability
EBITDA (TTM)
-123.807
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-284.18%
Operating margin (TTM)
-224.08%
Effective tax rate (TTM)
0.08%
Revenue per employee (TTM)
$880,000
Management effectiveness
Return on assets (TTM)
-15.28%
Return on equity (TTM)
-53.60%
Valuation
Price to revenue (TTM)
27.648
Price to book
3.38
Price to tangible book (TTM)
3.38
Growth
Revenue change (TTM)
-36.24%
Earnings per share change (TTM)
-14.97%
3-year revenue growth (CAGR)
-14.44%
10-year revenue growth (CAGR)
-11.12%
3-year earnings per share growth (CAGR)
-37.51%
10-year earnings per share growth (CAGR)
-6.06%
NKTR News
AllArticlesVideos
Nektar Therapeutics Q1 Earnings Call Highlights
MarketBeat·4 days ago
NEKTAR DEADLINE TODAY: ROSEN, A LEADING LAW FIRM, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important May 5 Deadline in Securities Class Action - NKTR
Newsfile Corp·7 days ago
NKTR DEADLINE NOTICE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important May 5 Deadline in Securities Class Action - NKTR
Newsfile Corp·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Nektar Therapeutics stock?
Nektar Therapeutics (NKTR) has a market cap of $2.7B as of May 12, 2026.
What is the P/E ratio for Nektar Therapeutics stock?
The price to earnings (P/E) ratio for Nektar Therapeutics (NKTR) stock is 0 as of May 12, 2026.
Does Nektar Therapeutics stock pay dividends?
No, Nektar Therapeutics (NKTR) stock does not pay dividends to its shareholders as of May 12, 2026.
When is the next Nektar Therapeutics dividend payment date?
Nektar Therapeutics (NKTR) stock does not pay dividends to its shareholders.
What is the beta indicator for Nektar Therapeutics?
Nektar Therapeutics (NKTR) has a beta rating of 1.25. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.